Skip to main content

Table 1 Patient characteristics at screening

From: Assessing the burden of treatment-emergent adverse events associated with atypical antipsychotic medications

Characteristic MDD
(n = 25)
Schizophrenia
(n = 17)
Total Patients
(N = 42)
Sex, n (%)    
 Male 9 (36) 11 (65) 20 (48)
 Female 16 (64) 6 (35) 22 (52)
Age, years    
 Mean (range) 46.4 (23–70) 45.5 (25–59) 46.0 (23–70)
Race/ethnicity,a n (%)    
 White 20 (80) 9 (53) 29 (69)
 African American 3 (12) 8 (47) 11 (26)
 Asian 1 (4) 0 (0) 1 (2)
 Hispanic/Latino 1 (4) 1 (6) 2 (5)
 Mixed race 0 (0) 1 (6) 1 (2)
Current atypical medications, n (%)b    
 Quetiapine 6 (24) 2 (12) 8 (19)
 Aripiprazole 6 (24) 2 (12) 8 (19)
 Risperidone 3 (12) 4 (24) 7 (17)
 Olanzapine 0 (0) 4 (24) 4 (10)
 Lurasidone 3 (12) 2 (12) 5 (12)
 Clozapine 1 (4) 2 (12) 3 (7)
 Ziprasidone 2 (8) 1 (6) 3 (7)
 Paliperidone 0 (0) 1 (6) 1 (2)
 Fluphenazine 0 (0) 1 (6) 1 (2)
 Asenapine 0 (0) 1 (6) 1 (2)
  1. a Participants could report more than 1 race
  2. b Total may not equal 100%. Four patients with schizophrenia and one patient with MDD reported using more than one AAP, and four patients with MDD and 2 patients with schizophrenia had a recent history of AAP use but were not currently using an AAP at screening. Each medication listed may include reference to 1 or more brand names, the chemical or generic name, and/or different formulations